Financial News
Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says
July 30, 2024 at 17:00 PM EDT
The study results on Leqembi, which Eisai shares with Biogen, also found that Alzheimer's patients who take the therapy get worse after they stop treatment.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
